Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Pegaspargase; Vincristine
- Indications Acute lymphoblastic leukaemia
- Focus Therapeutic Use
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2017 Planned End Date changed from 1 Jul 2017 to 30 Sep 2018.
- 22 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 30 Sep 2017.